Inst. Holders
50 funds
RAPT
RAPT Therapeutics, Inc.
—
12-mo target$58.00 (-0.0%)
High Impact Filing (7/10)3 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on RAPT right now — valuation, ownership and activity at a glance.
Inst. Value
$260.6M
Inst. Activity
0 buys / 3 sells
SEC Reports
1
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 5, 2026 earnings_calendar
RAPT Q2 2026 Earnings Scheduled — 2026-08-05
Mar 31, 2026 Inst.
BlackRock, Inc. — EXIT
0 shares ($0.00)
Mar 31, 2026 Inst.
Mar 18, 2026 SEC STATE STREET CORP — EXIT
0 shares ($0.00)
RAPT Therapeutics has filed Form 15 to terminate its SEC registration and suspend reporting obligations following its ac
15-12G — Impact 7/10
Mar 3, 2026 Insider
Wong Brian Russell disposed of 18,750 shares
PRESIDENT AND CEO
Mar 3, 2026 Insider
Young Rodney KB disposed of 80,250 shares
CHIEF FINANCIAL OFFICER
Mar 3, 2026 Insider
Giordano Michael F disposed of 799 shares
Director
Analyst ratings buy % -57.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jan 21, 2026 | Barclays | DOWNGRADE | Equal-Weight | 54% |
| Jan 21, 2026 | Leerink Partners | DOWNGRADE | Market Perform | 49% |
| Jan 20, 2026 | Wells Fargo | DOWNGRADE | Equal-Weight | 54% |
| Jan 20, 2026 | LifeSci Capital | DOWNGRADE | Market Perform | 50% |
| Jan 20, 2026 | TD Cowen | DOWNGRADE | Hold | 56% |
| Jan 20, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Jan 20, 2026 | Clear Street | DOWNGRADE | Hold | 49% |
| Dec 18, 2025 | TD Cowen | INITIATE | Buy | 56% |
| Nov 12, 2025 | JP Morgan | MAINTAIN | Overweight | 55% |
| Nov 7, 2025 | Barclays | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | 3 | 3 | 11 | 0 | 0 | 35% | |
| Jun 1, 2026 | 3 | 3 | 11 | 0 | 0 | 35% | |
| May 1, 2026 | 3 | 3 | 11 | 0 | 0 | 35% | |
| Apr 1, 2026 | 3 | 3 | 11 | 0 | 0 | 35% | |
| Mar 1, 2026 | 3 | 3 | 11 | 0 | 0 | 35% | |
| Feb 1, 2026 | 3 | 3 | 11 | 0 | 0 | 35% | |
| Jan 1, 2026 | 4 | 10 | 3 | 0 | 0 | 82% |
Price targets
Where 2 covering analysts think RAPT trades over the next 12 months.
$58.00 -0.0% upside Hold
Current$58.02 Low$58.00 Median$58.00 High$58.00 2 analysts
$58.00$58.00
Analyst rating Hold· 3.0/5 as of May 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 7.0/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
Clinical Trial
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
Phase Phase 2 — COMPLETED
Aug 5, 2026
earnings_calendar
RAPT Q2 2026 Earnings Scheduled — 2026-08-05
May 6, 2026
earnings_calendar
RAPT Q1 2026 Earnings Scheduled — 2026-05-06
Apr 1, 2026
Clinical Trial
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
Phase Phase 2 — TERMINATED
Apr 1, 2026
Clinical Trial
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
Phase Phase 2 — TERMINATED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Next Q | $-0.57 | $-0.72–$-0.43 | 10.2% | +12.5% | — | $0.0B | 2 |
| Current Q | $-1.03 | $-1.30–$-0.83 | 89.5% | -16.2% | — | $0.0B | 3 |
| Current FY | $-2.83 | $-2.95–$-2.74 | 88.9% | -14.3% | — | $0.0B | 3 |
| Next FY | $-2.71 | $-3.26–$-1.77 | 4.1% | +12.6% | — | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.027 | — |
| 7d ago | $-0.883 | -0.143 |
| 30d ago | $-0.883 | -0.143 |
| 60d ago | $-0.839 | -0.188 |
| 90d ago | $-0.762 | -0.264 |
Institutional ownership
Which big funds own RAPT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $260.6M total value (7,695,211 shares) as of 2025-Q4. Top holders: RTW, VANGUARD, STATE. Net buying activity: 16 institutions added/increased vs 1 reduced.
Top holders — 2025-Q4
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1,637,165 | $55.5M | 21.3% | EXIT -100.0% |
| VANGUARD GROUP INC | 1,186,791 | $40.2M | 15.4% | ADD +70.5% |
| STATE STREET CORP | 639,804 | $21.7M | 8.3% | EXIT -100.0% |
| CITADEL ADVISORS LLC | 591,802 | $20.0M | 7.7% | — |
| BlackRock, Inc. | 486,153 | $16.5M | 6.3% | EXIT -100.0% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 424,862 | $14.4M | 5.5% | — |
| FMR LLC | 275,758 | $9.3M | 3.6% | DOUBLED +12729.4% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 275,000 | $9.3M | 3.6% | — |
| GOLDMAN SACHS GROUP INC | 254,053 | $8.6M | 3.3% | DOUBLED +312.6% |
| GEODE CAPITAL MANAGEMENT, LLC | 239,790 | $8.1M | 3.1% | ADD +97.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | EXIT | 486,153 | 0 | -100.0% | $0.00 |
| STATE STREET CORP | EXIT | 639,804 | 0 | -100.0% | $0.00 |
| RTW INVESTMENTS, LP | EXIT | 1,637,165 | 0 | -100.0% | $0.00 |
| VANGUARD GROUP INC | ADD | 696,188 | 1,186,791 | +70.5% | $40.2M |
| STATE STREET CORP | DOUBLED | 37,383 | 639,804 | +1611.5% | $21.7M |
| BlackRock, Inc. | DOUBLED | 89,503 | 486,153 | +443.2% | $16.5M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 61,576 | 254,053 | +312.6% | $8.6M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 121,464 | 239,790 | +97.4% | $8.1M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 39,278 | 106,671 | +171.6% | $3.6M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 34,311 | 91,173 | +165.7% | $3.1M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | Wong Brian Russell | PRESIDENT AND CEO | D | 18,750 | — | — |
| Mar 3, 2026 | Young Rodney KB | CHIEF FINANCIAL OFFICER | D | 80,250 | — | — |
| Mar 3, 2026 | Giordano Michael F | Director | D | 799 | — | — |
| Mar 3, 2026 | Wong Brian Russell | PRESIDENT AND CEO | D | 7,500 | — | — |
| Mar 3, 2026 | Brockstedt Dirk G. | CHIEF SCIENTIFIC OFFICER | D | 2,500 | — | — |
| Mar 3, 2026 | GRAY MARY ANN | Director | D | 4,561 | — | — |
| Mar 3, 2026 | Brockstedt Dirk G. | CHIEF SCIENTIFIC OFFICER | D | 6,876 | — | — |
| Mar 3, 2026 | Giordano Michael F | Director | U | 4,956 | — | — |
| Mar 3, 2026 | GRAY MARY ANN | Director | D | 7,650 | — | — |
| Mar 3, 2026 | Lyons-Williams Lori | Director | D | 1,063 | — | — |
All RAPT filing & press-release reports (1)
- 15-12G reportMar 18, 2026